baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Cellectis SA/ US15117K1034 /

2024-06-03 7:51:52 PM	Chg. -0.07	Volume	Bid-	Ask-	High	Low
2.62USD	-2.60%	300 Turnover: 794	-Bid Size: -	-Ask Size: -	2.69	2.62

GlobeNewswire 05-29 Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

GlobeNewswire 05-28 Cellectis Reports Financial Results for First Quarter 2024

GlobeNewswire 05-27 Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

GlobeNewswire 05-13 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

GlobeNewswire 05-09 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire 05-06 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

GlobeNewswire 05-02 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

GlobeNewswire 04-29 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

GlobeNewswire 04-26 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...

GlobeNewswire 04-22 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...

GlobeNewswire 04-10 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Dis...

GlobeNewswire 04-08 Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and...

GlobeNewswire 03-14 Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updat...

GlobeNewswire 01-16 Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agre...

GlobeNewswire 01-04 Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro D...

GlobeNewswire 01-04 Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, ...

GlobeNewswire 2023-12-22 Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

GlobeNewswire 2023-12-09 Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-6...

GlobeNewswire 2023-12-05 Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actio...

GlobeNewswire 2023-11-17 Cellectis’ Shareholders Meeting to be Held on December 22, 2023

GlobeNewswire 2023-11-15 Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

GlobeNewswire 2023-11-06 Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

GlobeNewswire 2023-11-03 Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Target...

GlobeNewswire 2023-11-03 Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies a...

GlobeNewswire 2023-11-02 Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I ...

Cellectis SA/ US15117K1034 /

If you wish to receive reply to your feedback, please provide your email address.